X4 PHARMACEUTICALS INC (XFOR)
US98420X1037 - Common Stock
ChartMill assigns a Buy % Consensus number of 82% to XFOR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 4.13. This target is 725.32% above the current price.
XFOR was analyzed by 12 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about XFOR.
In the previous month the buy percentage consensus was at a similar level.
XFOR was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-06-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-31 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-04-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-12 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-17 | Stifel | Maintains | Buy -> Buy |
| 2023-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-10 | B. Riley Securities | Maintains | Buy |
| 2023-03-24 | Oppenheimer | Maintains | Outperform |
| 2023-03-22 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-03-22 | HC Wainwright & Co. | Maintains | Buy |
| 2022-12-22 | Cantor Fitzgerald | Initiate | Overweight |
| 2022-12-12 | Piper Sandler | Initiate | Overweight |
| 2022-11-30 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-19 | B. Riley Securities | Maintains | Buy |
| 2022-05-13 | HC Wainwright & Co. | Maintains | Buy |
| 2021-12-14 | HC Wainwright & Co. | Maintains | Buy |